These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12116552)

  • 41. [Systemic approach to investigation of levitra efficacy in patients with chronic prostatitis with erectile dysfunction].
    Aliaev IuG; Ronkin MA; Esilevskiĭ IuM; Zhuchenko TD; Demidko IuL; Krupinov GE; Shcherbanina VIu
    Urologiia; 2005; (2):53-60. PubMed ID: 15989030
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [PDE-5 inhibitor with improved pharmacokinetics. Far-reaching return to normality].
    MMW Fortschr Med; 2003 Mar; 145(11):56-7. PubMed ID: 12688198
    [No Abstract]   [Full Text] [Related]  

  • 43. Erectile dysfunction and coronary atherothrombosis in diabetic patients: pathophysiology, clinical features and treatment.
    Gazzaruso C
    Expert Rev Cardiovasc Ther; 2006 Mar; 4(2):173-80. PubMed ID: 16509813
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cyclic nucleotide phosphodiesterase 5 and sildenafil: promises realized.
    Manganiello V
    Mol Pharmacol; 2003 Jun; 63(6):1209-11. PubMed ID: 12761329
    [No Abstract]   [Full Text] [Related]  

  • 45. Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction.
    Francis SH; Corbin JD
    Urol Clin North Am; 2005 Nov; 32(4):419-29, vi. PubMed ID: 16291034
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction.
    Eardley I; Gentile V; Austoni E; Hackett G; Lembo D; Wang C; Beardsworth A
    BJU Int; 2004 Oct; 94(6):871-7. PubMed ID: 15476525
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phosphodiesterase 5 mechanisms and therapeutic applications.
    Burnett AL
    Am J Cardiol; 2005 Dec; 96(12B):29M-31M. PubMed ID: 16387563
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Management of erectile dysfunction in the cardiac patient].
    Gratzke C; Becker AJ; Park JW; Reich O; Waldkirch E; Schlenker B; Stief CG
    Dtsch Med Wochenschr; 2005 Dec; 130(50):2899-903. PubMed ID: 16342015
    [No Abstract]   [Full Text] [Related]  

  • 49. [In sex dysfunctions--not just a "male issue". Don't forget women].
    MMW Fortschr Med; 2003 Sep; 145(35-36):51. PubMed ID: 14584212
    [No Abstract]   [Full Text] [Related]  

  • 50. Tadalafil in the treatment of erectile dysfunction.
    Bella AJ; Brock GB
    Curr Urol Rep; 2003 Dec; 4(6):472-8. PubMed ID: 14622501
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Emergence and success of PDE5 inhibitors as effective therapy for erectile dysfunction.
    Manganiello V
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S1-3. PubMed ID: 15224126
    [No Abstract]   [Full Text] [Related]  

  • 52. Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease.
    Reffelmann T; Kloner RA
    Circulation; 2003 Jul; 108(2):239-44. PubMed ID: 12860892
    [No Abstract]   [Full Text] [Related]  

  • 53. Phosphodiesterase 5 (PDE 5) inhibitors for the treatment of male erectile disorder: attaining selectivity versus PDE6.
    Pissarnitski D
    Med Res Rev; 2006 May; 26(3):369-95. PubMed ID: 16388517
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations.
    Berner MM; Kriston L; Harms A
    Int J Impot Res; 2006; 18(3):229-35. PubMed ID: 16239897
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime.
    Ströberg P; Hedelin H; Ljunggren C
    Eur Urol; 2006 May; 49(5):900-7; discussion 907. PubMed ID: 16564126
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
    Carson CC
    BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular biology and pharmacology of PDE-5-inhibitor therapy for erectile dysfunction.
    Corbin JD; Francis SH
    J Androl; 2003; 24(6 Suppl):S38-41. PubMed ID: 14581493
    [No Abstract]   [Full Text] [Related]  

  • 58. In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit.
    Lau DH; Thompson CS; Morgan RJ; Mumtaz FH; Mikhailidis DP
    BJU Int; 2005 Dec; 96(9):1424. PubMed ID: 16287475
    [No Abstract]   [Full Text] [Related]  

  • 59. Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.
    Kukreja RC; Ockaili R; Salloum F; Yin C; Hawkins J; Das A; Xi L
    J Mol Cell Cardiol; 2004 Feb; 36(2):165-73. PubMed ID: 14871543
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors.
    Jackson G
    Am J Cardiol; 2005 Dec; 96(12B):32M-36M. PubMed ID: 16387564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.